N/A N=13 Effect of Acetazolamide and Furosemide on Obesity-induced Glomerular Hyperfiltration
Obesity-induced Hyperfiltration
Primary: Change in GFR (ml/Min) — 151; 152; 120; 150 ml/min
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=9 Effects of Obesity Surgery on Renal Function
Impaired Renal Function
Primary: Changes in Glomerular Renal Function After Weight Loss Surgery as Measured by 51Cr-EDTA Clearance — 0 Participants
Phase 4 N=32 Free Fatty Acid-Induced Hypertension in Obese Subjects With Type 2 Diabetes
Type 2 Diabetes · Hypertension
Primary: Changes in Systolic Blood Pressure During Initial Intralipid Infusion — 23; 13 mmHg
Phase 4 N=72 Effect of Farxiga on Renal Function and Size in Type 2 Diabetic Patients With Hyperfiltration
Diabetes Mellitus, Type 2
Primary: GFR (Glomerular Filtration Rate) Change After Treatment — 22; 1; 8; 0 ml/min/1.73m^2
N/A N=36 Exercise in Obese Diabetic Patients With Chronic Kidney Disease
Chronic Kidney Disease
Primary: Change in Proteinuria — -34; -133 mg/g creatinine — p=0.04
Phase 4 N=20 Angiotensin II Blockade and Inflammation in Obesity
Overweight · Obese · Prehypertension
Primary: Insulin Sensitivity by Intravenous Glucose Tolerance Testing (Change Over Time) — 0.253; -0.804 mu/L/min
Phase 2 N=60 Metformin in Kidney Disease
Chronic Kidney Disease · Cardiovascular Disease · Metabolic Syndrome
Primary: Change is Leptin to Adiponectin Ratio (LAR) — 2.2; 1.3; 1.3; 1.4 ng/micrograms
N/A N=57 Insulin-sensitive Obesity: Lessons From Longitudinal Data
Insulin Sensitivity/Resistance · Obesity
Primary: Insulin Sensitivity — 0.0105; -0.0076; 0.0041 micro mol/min/Kg/mU/L/year
N/A N=12 FFA Hypertension and Inflammation in Lean and Obese Subjects
Diabetes · Hypertension · Obesity
Primary: Change in Flow-mediated Dilation From Baseline to 4 Hours — 0.16; -3.2; -0.9; -2.4 percent change in diameter
Early Phase 1 N=46 Assessment of Renal Function by Multiparametric MRI
Renal Impairment
Primary: T1 Time — 1500 ms
Phase 4 N=51 Effect of VI-0521 (Qsymia®) on Glomerular Filtration Rate (GFR) in Overweight or Obese Healthy Subjects
Obesity
Primary: Change in iGFR (Glomerular Filtration Rate as Measured by Iohexol Clearance) From Baseline to End of Treatment — -14.92; 1.08 mL/min/1.73 m^2
N/A N=13 FFA-Induced Hypertension and Endothelial Dysfunction
Endothelial Dysfunction · Hypertension
Primary: Change in Systolic Blood Pressure to After Completing an 8-hour Normal Saline Infusion in Obese Normotensive Subjects. — 13 mmHg
N/A N=18 Renal Perfusion, Filtration and Oxygenation During Cardiopulmonary Bypass (CPB)
Complication of Extracorporeal Circulation · Renal Impairment
Primary: Renal Blood Flow (RBF) — 554; 524; 564; 558 ml per minute per 1.73 m2 body surface — p=0.638
N/A N=28 Daily Caloric Restriction and Intermittent Fasting in Overweight and Obese Adults With Autosomal Dominant Polycystic Kidney Disease
Polycystic Kidney, Autosomal Dominant
Primary: Feasibility to Enroll and Retain Participants — 122 Participants
Phase 2 N=10 Evaluation of Coffee Therapy for Improvement of Renal Oxygenation
Type1diabetes · Type1 Diabetes Mellitus · Diabetic Kidney Disease
Primary: Renal Oxygenation — 22.4; 22.5 s^-1
N/A N=95 Effect of Adipokines in Hemodialysis Patients
End Stage Renal Disease
Primary: Change in High Molecular Weight Adiponectin (HMW-A) Concentration in Plasma From Baseline to 6 Months — 38.3; -3.4 percent difference in geometric mean — p=0.047
Phase 4 N=44 Renoprotective Effects of Dapagliflozin in Type 2 Diabetes
Diabetes Mellitus, Type 2 · Diabetic Nephropathies
Primary: Glomerular Filtration Rate (GFR) in ml/Min — 104; 109 ml/min
Phase 2 N=16 SGLT2 Inhibitor Effects on Inflammation and Heart Disease in Obesity Pilot
Obesity · Pre-diabetes
Primary: Change in Adipose Pro-inflammatory T Helper Type 1 Cell Percentages After 3 Months — -1.6 Percentage of CD3+ T cells
N/A N=103 Mechanisms of Chronic Kidney Disease (CKD)-Induced Foam Cell Formation
Chronic Kidney Disease · Cardiovascular Disease
Primary: In Vitro Lipoprotein Functions — 20.8; 26.5 Percentage of cholesterol content
N/A N=80 Effects of Febuxostat on Adipokines and Kidney Disease in Diabetic Chronic Kidney Disease
Chronic Kidney Disease · Diabetes
Primary: Change in Thiobarbituric Acid Reactive Substance (TBARS) Concentration in Adipose Tissue From Baseline to 24 Weeks — 34.0; 44.6 percent difference in geometric mean…
Early Phase 1 N=15 Effect of Hyperglycemia on Microvascular Perfusion in Healthy Adults
Vascular Stiffness · Insulin Sensitivity
Primary: Change in Flow Mediated Dilation (FMD) Between Baseline and After 2 Hour Insulin Clamp — 11.8; 11.8; 8.9; 8.95 % change
N/A N=42 Acute Renal Injury During High Intensity Training
Acute Kidney Injury · Exercise
Primary: Change in Concentration of Proenkephalin-A From Baseline to 4 Time-points Surrounding the Workout — 1.65; 3.69; 2.50; 2.13 pmol/L
N/A N=61 Endothelial Dysfunction in Obese Children
Obesity · Atherosclerosis
Primary: Change From Baseline in Reactive Hyperemia Index at 5 and 10 Months — 1.9; 1.5; 2.01; 1.55 arbitrary units — p=<0.05
Phase 2 N=31 Empagliflozin and ACEi- Effects on Hyperfiltration: BETWEEN Study
Diabetes Mellitus, Type 1 · Diabetes Mellitus, Type 2 · Obesity
Primary: Glomerular Filtration Rate (GFR) Under Euglycaemic Conditions After 4 Weeks of Treatment With Either Empagliflozin Added to Ramipril or Placebo Added to Ramipril…
N/A N=16 Acute Exercise Effects in Obese Pregnancy
Pregnancy Complications · Obesity · Pre-Eclampsia
Primary: Oral Glucose Insulin Sensitivity (OGIS) Index — 405.0; 426.0; 418.9 uU/mL
N/A N=58 Obesity and Endogenous Oxalate Synthesis
Obesity
Primary: Urinary Oxalate Excretion — 24 mg/day
N/A N=34 Ultrafiltration Profiling and Outcomes Among Individuals on Maintenance Hemodialysis
End Stage Renal Disease
Primary: Occurrence of Intradialytic Hypotension (Intradialytic Hypotension Defined as Nadir Systolic BP <90 mmHg) — 578; 571 Number of occurrences — p=0.5
N/A N=20 Protection Against Insulin Resistance in Obesity
Obesity · Insulin Resistance
Primary: Insulin Sensitivity — 273; 817 nmol/kg FFM/min /(µU/mL Insulin)
N/A N=28 Mechanism Underlying Beta-cell Failure in Obese African Americans With History of Hyperglycemic Crises
Diabetes Mellitus, Type 2
Primary: First-Phase Insulin Release (FPIR) — 264; 339; 197; 359 microunits/ml
N/A N=38 Mineralocorticoid Receptor and Obesity Induced Cardiovascular Complications
Obesity · Insulin Resistance
Primary: Change From Baseline in Post-ischemic Dilatation — 9.6; 10.2; -1.2; -2.0 percent dilalation